Legleye S, Piontek D, Pampel F, Goffette C, Khlat M, Kraus L. Is there a cannabis epidemic model? Evidence from France, Germany and USA. Int J Drug Policy. 2014;25:1103–12.
Castaldelli-Maia JM, Martins SS, de Oliveira LG, van Laar M, de Andrade AG, Nicastri S. Use transition between illegal drugs among Brazilian university students. Soc Psychiatry Psychiatr Epidemiol. 2014;49:385–94.
Palamar JJ, Ompad DC, Petkova E. Correlates of intentions to use cannabis among US high school seniors in the case of cannabis legalization. Int J Drug Policy. 2014;25:424–35.
Crippa JA, Hallak JE, Zuardi AW. Marijuana, feijoada and the debate on drug legalization. Front Psychiatry. 2013;4:7.
Cruz JM, Boidi MF, Queirolo R. The status of support for cannabis regulation in Uruguay 4 years after reform: evidence from public opinion surveys. Drug Alcohol Rev. 2018;37(S1):S429–34.
Vuolo M. National-level drug policy and young people’s illicit drug use: a multilevel analysis of the European Union. Drug Alcohol Depend. 2013;131:149–56.
Fischer B, Kuganesan S, Room R. Medical Marijuana programs: implications for cannabis control policy—observations from Canada. Int J Drug Policy. 2015;26:15–9.
Fiala SC, Dilley JA, Firth CL, Mahler JE. Exposure to marijuana marketing after legalization of retail sales: Oregonians’ experiences, 2015–2016. Am J Public Health. 2018;108:120–7.
Subbaraman MS, Kerr WC. Marijuana policy opinions in Washington state since legalization: would voters vote the same way? Contemp Drug Probl. 2016;43:369–80.
Crippa JA, Crippa AC, Hallak JE, Martin-Santos R, Zuardi AW. ∆9-THC Intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:359.
Day D, Kuntz DJ, Feldman M, Presley L. Detection of THCA in oral fluid by GC-MS-MS. J Anal Toxicol. 2006;30:645–50.
Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128:64–70.
Campbell DW, Stewart S, Gray CEP, Ryan CL, Fettes P, McLandress AJ, et al. Chronic cannabis use and attentional bias: extended attentional capture to cannabis cues. Addict Behav. 2018;81:17–21.
Favretto D, Visentin S, Stocchero G, Vogliardi S, Snenghi R, Montisci M (2018) Driving under the influence of drugs: prevalence in road traffic accidents in Italy and considerations on “per se” limits legislation. Traffic Inj Prev. https://doi.org/10.1080/15389588.2018.1500018
Ramaekers JG. Driving under the influence of cannabis: an increasing public health concern. JAMA. 2018;319(14):1433–4.
Del Balzo G, Gottardo R, Mengozzi S, Dorizzi RM, Bortolotti F, Appolonova S, et al. “Positive” urine testing for cannabis is associated with increased risk of traffic crashes. J Pharm Biomed Anal. 2018;151:71–4.
Khashaba E, El-Helaly M, El-Gilany AH, Motawei SM, Foda S. Risk factors for non-fatal occupational injuries among construction workers: a case-control study. Toxicol Ind Health. 2018;34(2):83–90.
American Psychiatric Association. Diagnostic and statistical manual. 5th ed. Arlington: American Psychiatric Association; 2013.
Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: a review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4:75–81.
Cornelius JR, Chung T, Martin C, Wood DS, Clark DB. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav. 2008;13(11):1500–5.
Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011;13(1–2):123–9.
Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195–212.
Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;13(1):22–9.
Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. 2006;74:307–16.
Cooper K, Chatters R, Kaltenthaler E, Wong R. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess. 2015;19(56):1–130.
Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep. 2014;1(2):137–43.
Haney M, Cooper DZ, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557–65.
Haney M, Hart LC, Vosburg KS, Nasser J, Bennet A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158–70.
Allsop DJ, Copeland J, Linteris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as agonist replacement therapy during cannabis withdrawal—a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–90.
Milman G, Bergamascchi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, et al. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther Drug Monit. 2014;36:218–24.
Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes E. Dronabinol for treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1–3):142–50.
Haney M, Hart CL, Vosburg SK, Comer SD, Collins S, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197(1):157–68.
Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441–9.
Kim J, Grobelna A. Nabilone for chronic pain management: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017. https://www.cadth.ca/media/pdf/htis/oct-2011/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf. Accessed 20 Sept 2018.
Darmani NA. Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy-induced acute and delayed vomiting. Pharmaceuticals. 2010;3:2930–55.
Pergolizzi JV Jr, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467–77.
Micromedex Solutions. Physicians’ Desk Reference (PDR), 2018. http://www.micromedexsolutions.com/micromedex2/4.46.0/WebHelp/MICROMEDEX_2.htm#Document_help/PDR_document.htm.
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409–16.
Pertwee RG, Thomas A. Therapeutic applications for agents that act at CB1 and CB2 receptors. In: Reggio PH, editor. The cannabinoid receptors. 1st ed. New York: Humana Press; 2009. p. 361–92.
Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol. 2007;36:45–59.
Moher D, Liberati A, Tetzlaff J, Altan DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(6):e1000097.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60.
Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016;161:298–306.
Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology. 2016;233(13):2469–78.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2015. http://www.emcdda.europa.eu/edr2015. Accessed 20 Sept 2018.
Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;13(3):233–8.
Baldaçara L, Cogo-Moreira H, Parreira BL, Diniz TA, Milhomem JJ, Fernandes CC, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2016;77(3):398–406.
Shukla L, Bokka S, Shukla T, Kandasamy A, Chand P, Benegal V et al (2017) Benzodiazepine and “Z-drug” dependence: data from a tertiary care center. Prim Care Companion CNS Disord. 2017;19(1):16br02025. https://doi.org/10.4088/PCC.16br02025.
Castaldelli-Maia JM, Loreto AR, Guimarães-Pereira BBS, Carvalho CFC, Gil F, Frallonardo FP, Ismael F, et al. Smoking cessation treatment outcomes among people with and without mental and substance use disorders: an observational real-world study. Eur Psychiatry. 2018;52:22–8.
Loreto AR, Carvalho CFC, Frallonardo FP, Ismael F, Andrade AG, Castaldelli-Maia JM. Smoking cessation treatment for patients with mental disorders using CBT and combined pharmacotherapy. J Dual Diagn. 2017;13(4):238–46.